This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medidata Nearly Doubles Usage Of Its Clinical Trial Management System In Year Since Acquisition

During the first year of offering Medidata CTMS™, an innovative cloud-based clinical trial management system, Medidata Solutions (NASDAQ: MDSO) dramatically expanded its CTMS customer base and is launching a major product enhancement—a seamless integration of Medidata CTMS with Medidata Rave ®, a leading electronic data capture (EDC) and clinical data management system (CDMS).

With the integration, Medidata offers customers a single, out-of-the-box solution for EDC, CDM and CTM that can streamline their clinical operations in an easy-to-deploy, cloud-based platform. The CTMS was acquired by Medidata through its acquisition of Clinical Force in July 2011, and since then the number of active studies running on the platform has grown by more than 85 percent.

“Medidata CTMS fulfills our customers’ need for an innovative, scalable solution that brings the same type of efficiencies to clinical operations as the rest of the Medidata Clinical Cloud,” said Glen de Vries, president, Medidata Solutions. “Given that we continue to enhance Medidata CTMS’ functionality—most recently releasing an upgrade that seamlessly integrates with Medidata Rave—it is no surprise that the number of studies actively running on the platform has nearly doubled over the past year.”

The integration between Medidata CTMS and Rave increases the efficiency of study monitors and clinical research associates. Data is automatically pulled from Rave into Medidata CTMS monitor reports, limiting room for errors and cutting out redundancies in data entry, contributing to time savings and improved data quality. With an increase in the number of study monitors actively using the system today—in fact, 60 percent more compared to just one year ago—the new out-of-the-box integration translates into significant aggregate time savings for life science companies.

To support increased customer usage of this enhanced product, Medidata now offers its customers an eLearning course, Medidata CTMS for Monitors, which provides instruction on best practices for site monitoring tasks, as part of the Medidata University product training program.

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.52 -1.40%
FB $116.13 -0.51%
GOOG $691.00 -0.00%
TSLA $238.89 -3.60%
YHOO $36.27 -0.87%


Chart of I:DJI
DOW 17,713.31 -117.45 -0.66%
S&P 500 2,057.71 -18.10 -0.87%
NASDAQ 4,760.3210 -44.97 -0.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs